伊马替尼-话题@MedSci

#伊马替尼#

1篇内容 | 1929人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2246615, encodeId=ac0122466158f, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=d36711834e35' target=_blank style='color:#2F92EE;'>#阿思尼布#</a>, objectTitle=【JHO】伊马替尼治疗未达深度分子学反应的患者加入阿思尼布可改善反应, objectType=article, longId=858137, objectId=87bf85813e0f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401015/1728973098067_8538692.jpg, objectUrl=/article/show_article.do?id=87bf85813e0f, replyNumber=0, likeNumber=31, createdTime=2025-01-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bf85813e0f, moduleTitle=【JHO】伊马替尼治疗未达深度分子学反应的患者加入阿思尼布可改善反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bf85813e0f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2241643, encodeId=bd72224164338, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=17f512218193' target=_blank style='color:#2F92EE;'>#MR4.5#</a>, objectTitle=浙江省血液慢粒协作组开发含骨髓纤维化的模型以预测伊马替尼治疗CML的MR4.5, objectType=article, longId=854590, objectId=ee15854590ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240617/1718612054574_5579292.jpg, objectUrl=/article/show_article.do?id=ee15854590ae, replyNumber=0, likeNumber=30, createdTime=2024-12-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=ee15854590ae, moduleTitle=浙江省血液慢粒协作组开发含骨髓纤维化的模型以预测伊马替尼治疗CML的MR4.5, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee15854590ae)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2229224, encodeId=b4d52229224b0, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=d36711834e35' target=_blank style='color:#2F92EE;'>#阿思尼布#</a>, objectTitle=【AJH】letter to editor：伊马替尼仍是CML的最佳一线治疗, objectType=article, longId=845814, objectId=f0b98458143f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720503969171_8538692.jpg, objectUrl=/article/show_article.do?id=f0b98458143f, replyNumber=0, likeNumber=84, createdTime=2024-10-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f0b98458143f, moduleTitle=【AJH】letter to editor：伊马替尼仍是CML的最佳一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b98458143f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2228810, encodeId=9a4e22288106a, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a>, objectTitle=【Cancer】江倩/秦亚溱团队探索慢性期CML主要分子学反应后伊马替尼减量的影响, objectType=article, longId=845345, objectId=532d84534534, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240924/1727169494752_8538692.png, objectUrl=/article/show_article.do?id=532d84534534, replyNumber=0, likeNumber=80, createdTime=2024-10-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=532d84534534, moduleTitle=【Cancer】江倩/秦亚溱团队探索慢性期CML主要分子学反应后伊马替尼减量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=532d84534534)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2215879, encodeId=534e22158e920, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=a2825995022' target=_blank style='color:#2F92EE;'>#普纳替尼#</a> <a href='/topic/show?id=54d51168e0a3' target=_blank style='color:#2F92EE;'>#Ph+ ALL#</a>, objectTitle=JAMA | 普纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病一线治疗中的比较, objectType=article, longId=835397, objectId=022983539e18, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721401882759_6145188.png, objectUrl=/article/show_article.do?id=022983539e18, replyNumber=0, likeNumber=154, createdTime=2024-07-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=022983539e18, moduleTitle=JAMA | 普纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病一线治疗中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022983539e18)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213457, encodeId=4a39221345eb3, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a> <a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴细胞白血病#</a> <a href='/topic/show?id=22ab4850622' target=_blank style='color:#2F92EE;'>#帕纳替尼#</a>, objectTitle=JAMA：帕纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病的一线治疗中的比较, objectType=article, longId=833242, objectId=5708833242dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720172627148_92910.jpg, objectUrl=/article/show_article.do?id=5708833242dc, replyNumber=0, likeNumber=101, createdTime=2024-07-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5708833242dc, moduleTitle=JAMA：帕纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病的一线治疗中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5708833242dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211005, encodeId=c6f9221100557, content=<a href='/topic/show?id=eaea524e90e' target=_blank style='color:#2F92EE;'>#急性髓性白血病#</a> <a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>, objectTitle=【BCJ】伊马替尼联合强烈化疗治疗BCR::ABL1+ AML的预后较好, objectType=article, longId=831185, objectId=877883118514, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240621/1718953300480_5579292.jpg, objectUrl=/article/show_article.do?id=877883118514, replyNumber=0, likeNumber=104, createdTime=2024-06-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=877883118514, moduleTitle=【BCJ】伊马替尼联合强烈化疗治疗BCR::ABL1+ AML的预后较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=877883118514)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195016, encodeId=675c2195016fd, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=631411226536' target=_blank style='color:#2F92EE;'>#慢性髓性白血病（CML）#</a>, objectTitle=Haematologica：伊马替尼治疗对慢性髓性白血病儿童患者身高的影响, objectType=article, longId=817817, objectId=3f0381e8170a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221201/1669967618444_4754896.jpeg, objectUrl=/article/show_article.do?id=3f0381e8170a, replyNumber=0, likeNumber=77, createdTime=2024-03-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3f0381e8170a, moduleTitle=Haematologica：伊马替尼治疗对慢性髓性白血病儿童患者身高的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0381e8170a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189141, encodeId=6aa621891411a, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴细胞白血病#</a> <a href='/topic/show?id=ccdf93951a7' target=_blank style='color:#2F92EE;'>#达沙替尼#</a>, objectTitle=【Cancer】Ph+ ALL异基因移植后伊马替尼对比达沙替尼维持治疗的长期结局, objectType=article, longId=814389, objectId=d706814389c0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=d706814389c0, replyNumber=0, likeNumber=116, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d706814389c0, moduleTitle=【Cancer】Ph+ ALL异基因移植后伊马替尼对比达沙替尼维持治疗的长期结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d706814389c0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174877, encodeId=707f21e4877c5, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a> <a href='/topic/show?id=5dd28335eea' target=_blank style='color:#2F92EE;'>#胃肠道间质瘤#</a> <a href='/topic/show?id=7c6e10858461' target=_blank style='color:#2F92EE;'>#瑞派替尼#</a>, objectTitle=瑞派替尼二线治疗胃肠道间质瘤的疗效和安全性俱佳，尤其KIT Ex11突变，详解2023ASCO公布INTRIGUE中国桥接试验, objectType=article, longId=804834, objectId=a8b28048349a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=a8b28048349a, replyNumber=0, likeNumber=129, createdTime=2023-12-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a8b28048349a, moduleTitle=瑞派替尼二线治疗胃肠道间质瘤的疗效和安全性俱佳，尤其KIT Ex11突变，详解2023ASCO公布INTRIGUE中国桥接试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b28048349a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1008107, encodeId=cb1d100810edd, content=<a href='/topic/show?id=c52225680c6' target=_blank style='color:#2F92EE;'>#伊马替尼#</a>治疗<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>有点跨度大, objectTitle=Lancet子刊：不会吧？《我不是药神》中的伊马替尼居然还能治疗糖尿病！, objectType=article, longId=215774, objectId=4757215e7454, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021815/1629004415193_2299762.JPG, objectUrl=/article/show_article.do?id=4757215e7454, replyNumber=0, likeNumber=144, createdTime=2021-08-15, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4757215e7454, moduleTitle=Lancet子刊：不会吧？《我不是药神》中的伊马替尼居然还能治疗糖尿病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4757215e7454)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊马替尼

2020-05-29

梅斯管理员

#伊马替尼# #慢性髓性白血病# #阿思尼布#

【JHO】伊马替尼治疗未达深度分子学反应的患者加入阿思尼布可改善反应

2025-01-04

梅斯管理员

#伊马替尼# #慢性髓性白血病# #MR4.5#

浙江省血液慢粒协作组开发含骨髓纤维化的模型以预测伊马替尼治疗CML的MR4.5

2024-12-10发表于威斯康星

梅斯管理员

#伊马替尼# #慢性髓性白血病# #阿思尼布#

【AJH】letter to editor：伊马替尼仍是CML的最佳一线治疗

2024-10-04发表于上海

梅斯管理员

#伊马替尼# #慢性髓性白血病#

【Cancer】江倩/秦亚溱团队探索慢性期CML主要分子学反应后伊马替尼减量的影响

2024-10-01发表于上海

梅斯管理员

#伊马替尼# #普纳替尼# #Ph+ ALL#

JAMA | 普纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病一线治疗中的比较

2024-07-20发表于上海

梅斯管理员

#一线治疗# #伊马替尼# #急性淋巴细胞白血病# #帕纳替尼#

JAMA：帕纳替尼与伊马替尼在费城染色体阳性急性淋巴细胞白血病的一线治疗中的比较

2024-07-05发表于上海

梅斯管理员

#急性髓性白血病# #伊马替尼# #AML#

【BCJ】伊马替尼联合强烈化疗治疗BCR::ABL1+ AML的预后较好

2024-06-21发表于上海

梅斯管理员

#伊马替尼# #慢性髓性白血病（CML）#

Haematologica：伊马替尼治疗对慢性髓性白血病儿童患者身高的影响

2024-03-24发表于上海

梅斯管理员

#伊马替尼# #急性淋巴细胞白血病# #达沙替尼#

【Cancer】Ph+ ALL异基因移植后伊马替尼对比达沙替尼维持治疗的长期结局

2024-02-24发表于上海

梅斯管理员

#伊马替尼# #胃肠道间质瘤# #瑞派替尼#

瑞派替尼二线治疗胃肠道间质瘤的疗效和安全性俱佳，尤其KIT Ex11突变，详解2023ASCO公布INTRIGUE中国桥接试验

2023-12-14发表于上海

医者仁者

#伊马替尼#治疗#糖尿病#有点跨度大

Lancet子刊：不会吧？《我不是药神》中的伊马替尼居然还能治疗糖尿病！

2021-08-15